This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Headache
  • /
  • Targeted Nitric Oxide Synthase Inhibitors for Migr...

Targeted Nitric Oxide Synthase Inhibitors for Migraine

Read time: 1 mins
Published:31st Mar 2018
Author: Pradhan AA, Bertels Z, Akerman S.
Availability: Free full text
Ref.:Neurotherapeutics. 2018;15(2):391-401.
Targeted Nitric Oxide Synthase Inhibitors for Migraine

Nitric oxide (NO) is a small gaseous signaling molecule that has important biological effects. It has been heavily implicated in migraine; and the NO donor, nitroglycerin, has been used extensively as a human migraine trigger. Correspondingly, a number of components of the NO signaling cascade have been shown to be upregulated in migraine patients. NO is endogenously produced in the body by NO synthase (NOS), of which there are three isoforms: neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Based on the accumulating evidence that endogenous NO regulation is altered in migraine pathogenesis, global and isoform-selective inhibitors of NOS have been targeted for migraine drug development. This review highlights the evidence for the role of NO in migraine and focuses on the use of NOS inhibitors for the treatment of this disorder. In addition, we discuss other molecules within the NO signaling pathway that may be promising therapeutic targets for migraine.

Read abstract on library site    Access full article